Genetic variation, β-blockers, and perioperative myocardial infarction
Peter Nagele1, Stephen B Liggett
1Division of Clinical and Translational Research, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. nagelep@wustl.edu
Insights
Genetic variations impact how patients respond to beta-blocker therapy for preventing heart attacks after surgery. Understanding these genetic differences is crucial for optimizing beta-blocker use and patient safety.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Anesthesiology
Background:
- Perioperative myocardial infarction (MI) is a significant risk following noncardiac surgery, especially in patients with cardiovascular risk factors.
- Beta-blockers are traditionally used for prevention and treatment, but their efficacy and safety in this context are increasingly debated.
- The influence of individual genetic variability on beta-blocker response remains underappreciated in current clinical discussions.
Purpose of the Study:
- To review the impact of genetic polymorphisms in the adrenergic signaling pathway and CYP2D6 on beta-blocker therapy.
- To explore how these genetic variations influence the efficacy, safety, and toxicity of beta-blockers in preventing perioperative myocardial infarction.
- To highlight the importance of pharmacogenetics in tailoring beta-blocker treatment for surgical patients.
Main Methods:
- Review of molecular, cellular, and physiological consequences of genetic polymorphisms.
- Analysis of the role of adrenergic receptor gene variations.
- Examination of the impact of cytochrome P450 2D6 (CYP2D6) gene polymorphisms on drug metabolism.
Main Results:
- Genetic variations in the adrenergic signaling pathway significantly affect adrenergic receptor function and beta-blocker efficacy.
- Polymorphisms in CYP2D6 influence beta-blocker metabolism, leading to potential toxicity (poor metabolizers) or reduced efficacy (ultra-rapid metabolizers).
- These genetic factors are likely critical determinants of individual responses to beta-blocker therapy in the perioperative setting.
Conclusions:
- Interindividual genetic variation plays a substantial role in the clinical response to beta-blocker therapy.
- Pharmacogenetic considerations are essential for optimizing the use of beta-blockers in preventing and treating perioperative myocardial infarction.
- Personalized medicine approaches incorporating genetic profiling may improve outcomes and reduce adverse events in at-risk surgical patients.
Abstract:
Perioperative myocardial infarction is a common and potentially fatal complication after noncardiac surgery, particular among patients with cardiovascular risk factors. β-blockers have been considered a mainstay in prevention and treatment of perioperative myocardial infarction, yet recent evidence suggests that β-blockers may have an unfavorable risk profile in this setting, and the use has become controversial. What seems conspicuously absent from the current discussion is the appreciation of how much interindividual genetic variation influences the clinical response to β-blocker therapy. Genetic variation in the adrenergic signaling pathway is common, and has a major impact on adrenergic receptor function and β-blocker efficacy in other cardiovascular diseases, such as heart failure and hypertension. Genetic variation in the cytochrome P450 2D6, or CYP2D6, enzyme, which is responsible for the metabolism of most β-blockers, is also important and can lead to poor metabolizing of β-blockers (potential toxicity) or their ultra-rapid degradation (decreased efficacy). Here, we review the molecular, cellular, and physiologic consequences of polymorphisms in the adrenergic signaling pathway and CYP2D6 gene, and show that these are likely relevant factors influencing efficacy, safety, and toxicity of β-blocker therapy in prevention and treatment of perioperative myocardial infarction.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers